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Background & aims: The safety and effectiveness of a home parenteral nutrition (HPN) program
depends both on the expertise and the management approach of the HPN center. We aimed to
evaluate both the approaches of different international HPN-centers in their provision of HPN and
the types of intravenous supplementation (IVS)-admixtures prescribed to patients with chronic
intestinal failure (CIF).
Methods: In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%,
malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. The
HPN-provider was categorized as health care system local pharmacy (LP) or independent home care
company (HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral
nutrition, either commercially premixed (PA) or customized to the individual patient (CA), alone or plus
extra FE (PAFE or CAFE). Doctors of HPN centers were responsible for the IVS prescriptions.
Results: HCC (66%) was the most common HPN provider, with no difference noted between benign-CIF
and malignant-CIF. LP was the main modality in 11 countries; HCC prevailed in 4 European countries:
Israel, USA, South America and Oceania (p < 0.001). IVS-admixture comprised: FE 10%, PA 17%, PAFE 17%,
CA 38%, CAFE 18%. PA and PAFE prevailed in malignant-CIF while CA and CAFE use was greater in benign-
CIF (p < 0.001). PA þ PAFE prevailed in those countries where LP was the main HPN-provider and
CA þ CAFE prevailed where the main HPN-provider was HCC (p < 0.001).
Conclusions: This is the first study to demonstrate that HPN provision and the IVS-admixture differ
greatly among countries, among HPN centers and between benign-CIF and cancer-CIF. As both HPN
provider and IVS-admixture types may play a role in the safety and effectiveness of HPN therapy,
criteria to homogenize HPN programs are needed so that patients can have equal access to optimal
CIF care.
© 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.me parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An
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Home parenteral nutrition (HPN) is the primary and life-
saving treatment for patients with chronic intestinal failure
(CIF) [1]. Intestinal failure (IF) is defined as the “reduction of gut
function below the minimum necessary for the absorption of
macronutrients and/or water and electrolytes, such that intra-
venous supplementation (IVS) is required to maintain health
and/or growth” [2]. Chronic IF can be due to five pathophysio-
logical mechanisms (short bowel, intestinal fistulas, intestinal
dysmotility, intestinal mechanical occlusion or extensive small
bowel mucosa disease) which can originate from either non-
malignant (benign-CIF) or malignant (malignant-CIF) diseases
[2]. Patients with CIF require IVS for months, years or some-
times lifelong [1,2]. They are discharged onto HPN programs
which aim at providing evidence-based therapy, minimizing
HPN-related complications (such as central venous catheter
(CVC)-related infections and metabolic complications) and
maximizing the patient's quality of life (QoL) [3,4]. The Euro-
pean Society for Clinical Nutrition and metabolism (ESPEN)
guidelines on benign-CIF recommend that at discharge: patients
are metabolically stable, able physically and emotionally to cope
with the HPN therapy, and have an adequate home environ-
ment; patients should be cared for by a multidisciplinary team
with skills and experience in IF and HPN management; patient/
caregiver training for HPN management should be patient-
centered with a multidisciplinary approach, together with
written guidelines; HPN patients should have access to infusion
pumps or devices with specified safety features together with
ancillary products, safe compounding and delivery systems.
Thus, the safety and effectiveness of a HPN program depends on
the expertise and the management modalities available at the
HPN center.
It has been suggested that the management and the provi-
sion of HPN programs differ greatly among countries and
among HPN centers. However, only one study, performed in
2010, objectively described this feature [5]. There are no recent
data on the approaches of international CIF centers in the
methods routinely adopted for HPN provision. Using the ESPEN
database for CIF, we carried out an international cross-sectional
survey to evaluate the approaches of different international
HPN centers in their provision of HPN and the types of intra-
venous supplementation (IVS)-admixtures supplied to patients
with CIF.
2. Materials and methods
This international cross-sectional observational study was
part of a large survey developed by the Home Artificial Nutrition
and Chronic Intestinal Failure (HAN & CIF) special interest group
of ESPEN, aimed at investigating the applicability of the clinical
classification of CIF [6]. The recruitment of HPN centers, patient
inclusion criteria, modalities of data collection and recorded
items have already been extensively described [6] and are
summarized below.
2.1. Participating centers and patient inclusion criteria
Sixty-five HPN centers from 22 countries enrolled all adult pa-
tients (18 year old) who were dependent on HPN for either
benign-CIF or malignant-CIF on March 1st 2015. The term
malignant-CIF indicates the presence of an activemalignant disease
at time of enrollment on the study (and thus excludes patients in
whom the malignancy has been cured; these patients were sur-
veyed within the benign-CIF group).Please cite this article as: Pironi L et al., Home parenteral nutrition pro
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Data were collected into a structured questionnaire embedded
in an Excel (Microsoft Co., 2013) database, termed “the CIF Action
day”, available at the web page of the HAN&CIF group on the ESPEN
website [7].
Demographic, clinical, CIF, underlying disease, IVS and HPN
program characteristics were gathered and the clinical classifica-
tion of CIF was calculated for each patient [6]. The HPN-provider
was categorized as health care system local pharmacy (LP) or
home care company (HCC). The term HPN-provider referred to the
supplier of the IVS-admixture, infusion pump or other regulatory
device, the ancillaries required for infusion and CVC medication.
The IVS-admixture was categorized as: fluids and electrolytes (FE);
commercially premixed ready-to-use parenteral nutrition admix-
ture (PA); commercially premixed parenteral nutrition admixture
plus extra FE (PAFE); parenteral nutrition admixture customized
(tailored) to the individual patient requirements (CA); parenteral
nutrition admixture customized to the individual patient re-
quirements alone or plus extra FE (CAFE).
2.3. Ethical statement
The research was based on anonymized information taken from
patient records at the time of data collection. The study was con-
ducted with full regard to confidentiality of the individual patient.
Ethical committee approval was obtained by the individual HPN
centers according to local regulations. Collected data were used
only for the study purpose. The identity of the contributing centers
has also been anonymized for data analysis and presentation.
2.4. Statistical analysis
The daily mean volume and energy of IVS were calculated as
follows: daily total volume (mL/day) or energy (kcal/
day) ¼ amount per day of infusion x number of infusions per
week/7; daily volume or energy per kg of patient body weight
(mL/kgBW/day or kcal/kgBW/day) ¼ amount per day of infusion x
number of infusions per week)/7/kg patient body weight. The
patients' body mass index (BMI) was calculated by Quetelet's
formula (weight (kg)/height (m2).
Data are reported as mean ± standard deviation (SD) and as
absolute and relative frequencies. The non-parametric Kruskal
Wallis test, the Fisher's exact test and the Chi-square test were
applied where appropriate.
The IBM SSPS Statistics package for Windows, version 23.0 (BM
Co., Armonk, NY, USA) was used for the analyses. Two-tailed P
values less than 0.05 were considered as statistically significant.
3. Results
3.1. Participating centers and patient cohorts
A total of 3239 patients were included, 2919 with benign-CIF
(90.1%) and 320 with malignant-CIF (9.9%) (Table 1). All the HPN
centers enrolled benign-CIF patients, while only 45 centers
enrolled malignant-CIF patients. The malignant-CIF cohort had
statistically significant older age, lower BMI, shorter duration of
HPN, IVS of greater daily volume and energy, and a 10-times greater
occurrence of patients with IF due to mechanical obstruction
(Table 2). In both benign-CIF and malignant-CIF, two-thirds of pa-
tients were females.
In the benign-CIF cohort, the underlying diseases were Crohn's
disease (22.4%), mesenteric ischemia (17.7%), surgical complica-
tions (15.8%), primary chronic intestinal pseudo-obstruction (9.7%),vision modalities for chronic intestinal failure in adult patients: An
9.03.010
Table 1
Patients on home parenteral nutrition for chronic intestinal failure (CIF) due to non-
malignant (benign) or malignant disease, enrolled by countries contributing in the
survey.
Total
n.
Benign-CIF
n. (%)
Malignant-CIF
n. (%)
UK 781 738 (94.5) 43 (5.5)
France 478 441 (92.3) 37 (7.7)
Italy 362 326 (90.1) 36 (9.9)
Poland 283 224 (79.2) 59 (20.8)
Denmark 262 233 (88.9) 29 (11.1)
The Netherlands 257 229 (89.1) 28 (10.9)
Spain 43 40 (93.0) 3 (7.0)
Slovenia 39 31 (79.5) 8 (20.5)
Sweden 25 24 (96.0) 1 (4.0)
Hungary 22 20 (90.9) 2 (9.2)
Belgium 21 21 (100) 0
Germany 10 1 (10) 9 (90)
Bulgaria 5 4 (80) 1 (20)
Croatia 3 3 (100) 0
Lithuania 3 2 (66.7) 1 (33.3)
USA 429 389 (90.7) 40 (9.3)
Israel 90 71 (78.9) 19 (21.1)
Mexico 4 3 (75) 1 (25)
Argentina 44 44 (100) 0
Brazil 7 7 (100) 0
Australia 44 41 (93.2) 3 (6.8)
New Zealand 27 27 (100) 0
Total 3239 2919 (90.1) 320 (9.9)
L. Pironi et al. / Clinical Nutrition xxx (xxxx) xxx4post-radiation enteritis (7.3%), others (21.3%, with <3% each-one)
and not reported (5.9%). In the malignant-CIF cohort, the type of
active cancer was not specified in 62% cases, gastrointestinal (28%)
and extra-abdominal (10%). Concurrent enteritis due to radio- or
chemo-therapy was described in 5% of cases and peritoneal carci-
nomatosis was reported in 12%.Table 2
Characteristics of the cohorts of patients with chronic intestinal failure (CIF) enrolled
in the study: patients withoutmalignant disease (Benign-CIF), n. 2919; patients with
a malignant disease (Malignant-CIF), n.320.
Benign-CIF Malignant-CIF P
Gender 0.202
Males 36.8% 39.45
Females 63.2% 60.6%
Age, years 54.9 ± 16.0 60.6 ± 13.5 <0.001
BMI, kg/m2 22.2 ± 4.4 21.5 ± 4.4 0.002
HPN duration, months 58.1 ± 71.5 17.1 ± 30.9 <0.001
Pathophysiological mechanism of IF <0.001
SBS-J 38.6% 28.8%
SBS-JC 19.9% 9.7%
SBS-JIC 5.9% 2.8%
Fistulas 7.0% 3.4%
Dysmotility 17.5% 3.4%
Mechanical Obstruction 4.4% 45.9%
Mucosal Disease 6.8% 5.9%
IVS volume, mL/day 1877.0 ± 1016.6 1967.6 ± 817.8 0.004
IVS energy, kcal/day 1088.0 ± 649.4 1315.9 ± 560.9 <0.001
Clinical classification of CIF (IVS, mL/day) <0.001
FE1, 1000 5.8% 3.1%
FE2, 1001-2000 2.2% 1.3%
FE2, 2001-3000 0.5% 0
FE4, >3000 0.3% 0
PN1, 1000 15.9% 10.3%
PN2, 1001-2000 40.9% 47.2%
PN3, 2001-3000 23.1% 29.4%
PN4, >3000 11.3% 8.8%
BMI, body mass index; HPN, home parenteral nutrition; SBS-J, short bowel syn-
drome with end jejunostomy; SBS-JC, short bowel syndrome with jejuno-colon
anastomosis; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis and
total colon: IVS, intravenous supplementation; FE, fluid and electrolytes; PN,
parenteral nutrition.
Please cite this article as: Pironi L et al., Home parenteral nutrition pro
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The HPN-provider was LP in 1111 (34.4%) and HCC in 2117
(65.6%) patients (not reported in 11). The IVS-admixture type was
FE in 312 (9.7%), PA in 556 (17.2%), PAFE in 541 (16.8%), CA in 1227
(37.9%) and CAFE in 595 (18.4%) cases. The IVS-admixture types
significantly differed between the twomodalities of HPN provision;
when the HPNwas provided by a HCC, the IVS-admixtures were CA
or CAFE in two-thirds of cases, while PA or PAFE accounted for more
than 50% of the IVS-admixtures provided by the LP (Table 3).
3.3. HPN-providers and IVS-admixture types by countries
HCCs provided all HPN in the UK and Israel, were almost
exclusive providers (80% of patients) in the USA, Mexico and
South America, and were the main providers (56e63% of cases) in
France, Italy, Poland and Oceania. LPs provided all the HPN pro-
grams in Denmark, two thirds of programs in the Netherlands and
more than 90% of cases in the other 9 European countries which
contributed to the survey (Fig. 1).
In those countries, except Poland, where most or all the HPN
programs were provided by a HCC, CA and CAFE represented more
than 50% of the IVS-admixtures. Where the LP was the main HPN-
provider, PA and PAFE prescription prevailed (Fig. 2).
3.4. HPN-providers and IVS-admixture types by the nature of the
underlying disease
The percentage split of the two HPN-providers did not differ
between benign-CIF and malignant-CIF, while CA and CAFE were
the IVS-admixture types in almost two-thirds of benign-CIF and PA
and PAFE were the IVS-admixture types in more than 50% of
malignant-CIF (Fig. 3).
4. Discussion
This large international survey demonstrates that the modality
of HPN provision and the type of IVS-admixture supplied differ
greatly among countries, among HPN centers and between benign-
CIF and malignant-CIF. Although it has been long suggested that
HPN management is not homogeneous between countries, as well
as among HPN centers within an individual country, this is the first
study to provide objective data to confirm the significant variation
in practice that exists in HPN provision. The strengths of the study
are the large numbers of participating countries and the worldwide
distribution of contributing HPN-centers and enrolled patients. ATable 3
Intravenous supplementation (IVS)-admixture type by home parenteral nutrition
(HPN)-provider in patients with chronic intestinal failure (P < 0.001).
Total n. FE n.
(%)
PA n.
(%)
PAFE n.
(%)
CA n. (%) CAFE n. (%) P
HCC 2117 224
(10.5)
149
(7.0)
304
(14.3)
906 (42.8) 534 (25.2) <0.001
LP 1111 88 (7.9) 407
(36.6)
237
(21.3)
318 (28.6) 61 (5.4)
HCC, home care company.
LP, health care system local pharmacy.
FE, fluids and electrolytes.
PA, commercially premixed ready-to-use parenteral nutrition admixture.
PAFE, commercially premixed ready-to-use parenteral nutrition admixture plus
extra fluids and electrolytes.
CA, parenteral nutrition admixture customized (tailored) to the individual patient
requirements.
CAFE, parenteral nutrition admixture customized (tailored) to the individual patient
requirements plus extra fluids and electrolytes.
vision modalities for chronic intestinal failure in adult patients: An
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Fig. 1. Home parenteral nutrition (HPN)-providers by countries in patients with
chronic intestinal failure. LP, health care system local pharmacy. HCC, home care
company. (P < 0.001). Europe others: Belgium, Bulgaria, Croatia, Germany, Hungary,
Lithuania, Slovenia, Spain, Sweden. Oceania: Australia, New Zealand. S. America:
Argentina, Brazil.
L. Pironi et al. / Clinical Nutrition xxx (xxxx) xxx 5potential limitation of the study is the relatively small number of
malignant-CIF patients recruited, in comparison with those with
benign-CIF (Table 1). Notably, the percentage of patients with
malignant-CIF in this study was lower than that expected
compared to previous published data [8e13]; this could be due to
the voluntary basis of HPN center participation possibly attracting
primarily those centers mainly caring for patients with benign-CIF.
Indeed, it is possible that patients with malignant-CIF are primarily
managed by oncologists or internists, outside established HPN or
CIF centers. Another explanation could be that, in previous surveys
on HPN prevalence, a significant percentage of patients with a
diagnosis of cancer were not actually felt to have CIF, but had been
placed on HPN because of refusal of an otherwise functioning
enteral tract or simply because they already had a CVC positioned
for chemotherapy. However, as expected, the benign-CIF and the
malignant-CIF cohorts of the present study consistently differed in
all their clinical and IVS characteristics, thus supporting that the
malignant-CIF cohort is representative of those patients typicallyFig. 2. Intravenous supplementation (IVS)-admixture type by countries in patients
with chronic intestinal failure. FE, fluids and electrolytes; PA, commercially premixed
ready-to-use parenteral nutrition admixture; PAFE, commercially premixed ready-to-
use parenteral nutrition admixture plus extra fluids and electrolytes; CA, parenteral
nutrition admixture customized (tailored) to the individual patient requirements;
CAFE, parenteral nutrition admixture customized (tailored) to the individual patient
requirements plus extra fluids and electrolytes (P < 0.001). Europe others: Belgium,
Bulgaria, Croatia, Germany, Hungary, Lithuania, Slovenia, Spain, Sweden. Oceania:
Australia, New Zealand. S. Am.: Argentina, Brazil.
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supplementation (Table 2).
Importantly, our data demonstrated an association between the
prescribed IVS-admixture type and the modality of HPN-provision.
Commercially PA or PAFE were more frequently used when the LP
was the HPN-provider, while CA or CAFE were more frequently
used when the HPN-provider was a HCC (Table 3). This would
indicate that, when required, a HCC is readily able to provide an
IVS-admixture tailored to the individual patient's needs. Indeed, as
CIF is a rare condition, not all the LP may have developed the
expertise and/or implemented the facilities to produce CA in a
sufficient quantity to overcome the production costs.
The data confirm that the modality of HPN provision differ
greatly among countries, with a range of 0e100% of cases for both
HCC and LP (Fig. 1). The non-homogeneous provision modality
within individual countries indicates that differences may exist
also among individual HPN centers. The association between the
modality of HPN provision and the IVS-admixture types reported
in the total cohort was also observed within the individual
countries (Fig. 2). The primary aims of an HPN program are pre-
vention of HPN-related complications and maximization of the
patient/family QoL [3]. The protocol for patient/caregiver training
and the facilities and ancillaries for IVS management may be very
relevant to the CVC-related complications and the availability of a
portable infusion pump may significantly change the QoL of pa-
tients [3]. Differences between means of HPN provision may
therefore have implications for the safety and efficacy of an HPN
program. This suggests that criteria for the implementation of
HPN provision should be formally devised in order to homogenize
this feature of the HPN program and to give patients the same
opportunity to receive appropriate HPN therapy regardless of
where they live.
The results further demonstrated that the IVS-admixture type but
not the HPN-provider differed between benign-CIF and malignant-
CIF. The IVS-admixtures tailored to the patient requirements (CA
and CAFE) were mainly used in benign-CIF, while premixed (ready-
to-use) IVS-admixture (PA and PAFE) were mainly used in
malignant-CIF (Fig. 3). This difference may be due to the character-
istics of the two patient populations, in terms of pathophysiological
mechanisms of IF as well as in the aims of the HPN program and the
expected patient outcome. The clinical scenarios of benign-CIF and
malignant-CIF are quite different. In malignant-CIF, the cause of IF
was more homogeneous, being represented by mechanical
obstruction in almost 50% of cases, often due to peritoneal carcino-
matosis. In benign-CIF, the mechanisms of IF were represented by
SBS and fistula in almost 70% of patients and the oral food and
beverage intake and the intestinal fluid and electrolytes losses may
greatly differ among patients, particularly those with benign disease,
highlighting their need for tailored PN prescriptions [6]. Further-
more, patients with benign-CIF have a high survival probability and
may have a high chance of intestinal rehabilitation, with most being
independent of a caregiver or any home healthcare assistance [3].
Thus, patients with benign disease often require fine tuning of the
HPN program and a tailored IVS-admixture in order to maximize the
prevention of long-termmetabolic complications as well as the daily
time free of IVS infusion. In patients withmalignant-CIF, HPNmay be
required while receiving cancer-directed treatment and/or receiving
palliative care [4]. The expected duration of HPN is much shorter,
either because of a transient need related to cancer treatment plans
or to the short life expectancy of advanced cancer. These patients are
often home-bound, dependent on a caregiver and require home
healthcare assistance; hence rapid discharge from hospital with a
pre-mixed formula is often clinically appropriate and in the patients'
best interest. The lack of differences in HPN-provider between
benign-CIF and malignant-CIF was probably due to the bias in thevision modalities for chronic intestinal failure in adult patients: An
9.03.010
Fig. 3. Home parenteral nutrition (HPN)-provider (P ¼ 0.083) and intravenous supplementation (IVS)-admixture type (P < 0.001) by nature of the underlying disease in patients
with chronic intestinal failure. HPN-provider: LP, health care system local pharmacy. HCC, home care company. IVS-admixture: FE, fluids and electrolytes; PA, commercially
premixed ready-to-use parenteral nutrition admixture; PAFE, commercially premixed ready-to-use parenteral nutrition admixture plus extra fluids and electrolytes; CA, parenteral
nutrition admixture customized (tailored) to the individual patient requirements; CAFE, parenteral nutrition admixture customized (tailored) to the individual patient requirements
plus extra fluids and electrolytes.
L. Pironi et al. / Clinical Nutrition xxx (xxxx) xxx6enrollment of the HPN centers that were mostly devoted to benign-
CIF, such that the same HPN provider would be used for all patients
under the center's care.
In conclusion, the modality of HPN provision and the IVS-
admixture types differ greatly among countries, among HPN cen-
ters and between benign-CIF and malignant-CIF. As both HPN
provider and IVS-admixture types may play a role in the safety and
effectiveness of HPN therapy, criteria to homogenize HPN programs
are needed, both within and between countries so that patients can
have equal access to optimal CIF care.
Contributing coordinators and centers by country
Argentina
Adriana N. Crivelli, Hector Solar Mu~niz; Hospital Universitario
Fundacion Favaloro, Buenos Aires
Australia
Brooke R. Chapman; Austin Health, Melbourne
Lynn Jones; Royal Prince Alfred Hospital, Sydney
Margie O'Callaghan; Flinders Medical Centre, Adelaide
Emma Osland, Ruth Hodgson, Siobhan Wallin, Kay Lasenby;
Royal Brisbane and Women's Hospital, Herston
Belgium
Andre Van Gossum: Ho^pital Erasme, Brussels
Brazil
Andre Dong Won Lee; Hospital das Clinicas da Faculdade de
Medicina da Universidade de S~ao Paulo, S~ao Paulo
Bulgaria
Maryana Doitchinova-Simeonova; Bulgarian Executive Agency
of Transplantation, Sofia
Croatia
Zeljko Krznaric; University Hospital Centre Zagreb, Zagreb
Denmark
Henrik Højgaard Rasmussen; Center for Nutrition and Bowel
Disease, Aalborg University Hospital, Aalborg
Chrisoffer Brandt, Michael Staun; Rigshospitalet, Copenhagen
France
Cecile Chambrier; Hospices Civils de Lyon, Centre Hospitalier
Lyon Sud, Lyon
Francisca Joly, Vanessa Boehm, Julie Bataille, Lore Billiauws;
Beaujon Hospital, Clichy
Florian Poullenot; CHU de Bordeaux, Ho^pital Haut-Leve^que,
Pessac
Stephane M. Schneider; CHU Archet, Nice
David Seguy; CHRU de Lille, Lille
Ronan Thibault; Nutrition unit, CHU Rennes, Nutrition Metab-
olisms and Cancer institute, NuMeCan, INRA, INSERM, Universite
Rennes, RennesPlease cite this article as: Pironi L et al., Home parenteral nutrition pro
international survey, Clinical Nutrition, https://doi.org/10.1016/j.clnu.201Germany
Jann Arends; Tumor Biology Center, Freiburg
Hungary
Laszlo Czako, Tomas Molnar, Mihaly Zsilak-Urban; University of
Szeged, Szeged
Ferenc Izbeki; Szent Gy€orgy Teaching Hospital of County Fejer,
Szekesfehervar
Peter Sahin, Gabor Udvarhelyi; St. Imre Hospital, Budapest
Eszter Schafer; Magyar Honvedseg Egeszsegügyi K€ozpont
(MHEK), Budapest
Israel
Miriam Theilla; Rabin Medical Center, Petach Tikva
Italy
Anna Simona Sasdelli, Loris Pironi; St. Orsola University Hospi-
tal, Bologna
Umberto Aimasso, Merlo F. Dario; Citta della Salute e della Sci-
enza, Torino
Valentino Bertasi, Luisa Masconale; ULSS 22 Ospedale Orlandi,
Bussolengo
Francesco W. Guglielmi, Nunzia Regano; San Nicola Pellegrino
Hospital, Trani
Paolo Orlandoni; INRCA e IRCCS, Ancona
Maria C. Pagano, Santarpia Lidia, Lucia Alfonsi; Federico II Uni-
versity, Napoli, Italy
Corrado Spaggiari; AUSL di Parma, Parma
Marina Taus, Debora Busni; Ospedali Riuniti, Ancona
Lithuania
Gintautas Kekstas; Vilnius University Hospital Santariskiu
Clinics, Vilnius
Mexico
Aurora E. Serralde-Zú~niga; Instituto Nacional de Ciencias
Medicas y Nutricion Salvador Zubiran, Mexico City
New Zealand
Lyn Gillanders; Auckland City Hospital, Auckland
Poland
Marek Kunecki; M. Pirogow Hospital, Lodz
Przemysław Matras; Medical University of Lublin, Lublin
Konrad Matysiak; H.Swie˛cicki University Hospital, Poznan
Kinga Szczepanek; Stanley Dudrick's Memorial Hospital,
Skawina
Anna Zmarzly; J. Gromkowski City Hospital, Wroclaw
Slovenia
Nada Rotovnik Kozjek; Institute of Oncology, Ljubljana
Spain
Marta Bueno; Hospital Universitario Arnau de Vilanova, Lleida
Cristina Cuerda; Hospital General Universitario Gregorio Mar-
a~non, Madrid
Carmen Garde; Hospital Universitario Donostia, San Sebastianvision modalities for chronic intestinal failure in adult patients: An
9.03.010
L. Pironi et al. / Clinical Nutrition xxx (xxxx) xxx 7Nuria M. Virgili; Hospital Universitari de Bellvitge, Barcelona
Gabriel Olveira; IBIMA, Hospital Regional Universitario de
Malaga, Universidad de Malaga, Malaga
Ma Estrella Petrina Jauregui; Complejo Hospitalario de Navarra,
Pamplona
Alejandro Sanz-Paris; Miguel Servet Hospital, Zaragoza
Jose P. Suarez-Llanos; Hospital Universitario Nuestra Se~nora de
Candelaria, Santa Cruz de Tenerife
Ana Zugasti Murillo; Hospital Virgen del Camino, Pamplona
Sweden
Lars Ellegard; Sahlgrenska University Hospital, Gothenburg
The Netherlands
Mireille Serlie, Cora Jonker; Academic Medical Center,
Amsterdam
Geert Wanten; Radboud University Medical Center, Nijmegen
United Kingdom
Sheldon C. Cooper; University Hospitals Birmingham NHS
Foundation Trust, Birmingham
Joanne Daniels; Nottingham University Hospital NHS Trust,
Nottingham
Simona Di Caro, Niamh Keane, Pinal Patel; University College
Hospital, London
Alastair Forbes; Norfolk and Norwich University Hospital,
Norwich
Sarah-Jane Hughes; Regional Intestinal Failure Service, Belfast
Health and Social Care Trust, Northern IrelandAmelia Jukes, Rachel
Lloyd; University Hospital of Wales, Cardiff
Simon Lal, Arun Abraham, Gerda Garside, Michael Taylor; Sal-
ford Royal NHS Foundation Trust, Salford
Jian Wu, Trevor Smith, Charlotte Pither, Michael Stroud; Uni-
versity Hospital Southampton NHS Foundation Trust, Southampton
Nicola Wyer, Reena Parmar, Nicola Burch; University Hospital,
Coventry
Sarah Zeraschi; Leeds Teaching Hospitals NHS Trust, Leeds
United States of America
Charlene Compher; Hospital of the University of Pennsylvania,
Philadelphia, PA
Darlene Kelly; Mayo Clinic College of Medicine, Rochester, MN
Denise Jezerski, Ezra Steiger; Cleveland Clinic Foundation,
Cleveland, OH
Statistical analysis performed by: Dr. Marianna Mastroroberto,
MD, PhD; Department of Medical and Surgical Sciences, University
of Bologna, Italy.
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